Literature DB >> 4758541

Thrombosis and oral contraceptives: possible predisposition.

B Astedt, S Isacson, I M Nilsson, M Pandolfi.   

Abstract

The coagulation factors and components of the fibrinolytic system were examined in 31 women with a previous history of phlebographically-verified thrombosis during the use of oral contraceptives of the combined type. Special attention was given to the histochemically-determined fibrinolytic activator content of the wall of biopsy specimens of superficial veins. None of the patients was taking contraceptives at the time of the investigation. Pathological changes, particularly in the fibrinolytic defence system, were found in most of the patients. They may be regarded as predisposed to thrombosis, and one might wonder whether these patients would sooner or later have had their thrombosis even if they had not used contraceptives. The concentration of antithrombin III was normal, indicating that this test is of no value for detecting patients predisposed to thrombosis, who should preferably not take oral contraceptives.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4758541      PMCID: PMC1587647          DOI: 10.1136/bmj.4.5893.631

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  25 in total

1.  The histological localisation of fibrinolysin activator.

Authors:  A S TODD
Journal:  J Pathol Bacteriol       Date:  1959-07

2.  Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system.

Authors:  I M NILSSON; H KROOK; N H STERNBY; E SODERBERG; N SODERSTROM
Journal:  Acta Med Scand       Date:  1961-03

3.  The fibrin plate method for estimating fibrinolytic activity.

Authors:  T ASTRUP; S MULLERTZ
Journal:  Arch Biochem Biophys       Date:  1952-10       Impact factor: 4.013

4.  Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis.

Authors:  S Isacson; I M Nilsson
Journal:  Acta Chir Scand       Date:  1972

5.  Implications of depressed antithrombin-3 activity associated with oral contraceptives.

Authors:  T F Zuck; J J Bergin; J M Raymond; W R Dwyre
Journal:  Surg Gynecol Obstet       Date:  1971-10

6.  Assay of progressive antithrombin in plasma.

Authors:  U Abildgaard; K Gravem; H C Godal
Journal:  Thromb Diath Haemorrh       Date:  1970-10-31

7.  Oral contraceptives and thromboembolism.

Authors:  L E Moses
Journal:  JAMA       Date:  1969-04-28       Impact factor: 56.272

8.  Increased platelet adhesiveness in recurrent venous thrombosis and pulmonary embolism.

Authors:  J Hirsh; J A McBride
Journal:  Br Med J       Date:  1965-10-02

9.  Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.

Authors:  C B Laurell
Journal:  Anal Biochem       Date:  1966-04       Impact factor: 3.365

10.  Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs.

Authors:  W H Inman; M P Vessey; B Westerholm; A Engelund
Journal:  Br Med J       Date:  1970-04-25
View more
  5 in total

1.  Oral contraceptives and thromboembolic disease.

Authors:  S V Pizzo
Journal:  West J Med       Date:  1986-09

2.  Thromboembolism and oral contraceptives.

Authors: 
Journal:  Br Med J       Date:  1974-02-09

3.  Effect of the menstrual cycle, oral contraception and pregnancy on forearm blood flow, venous distensibility and clotting factors.

Authors:  R Fawer; A Dettling; D Weihs; H Welti; J L Schelling
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

4.  The effect of low-dose estroprogestinic preparations on prothrombin complex factors: no significant increase after an 8-month trial.

Authors:  A Girolami; M Procidano; M Vicariotto; G Cappellato; T Vicari
Journal:  Blut       Date:  1985-03

5.  Deep venous thrombosis of the arm: a study of coagulation and fibrinolysis.

Authors:  S B Sundqvist; U Hedner; H K Kullenberg; S E Bergentz
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.